Philanthropy and Advocacy-Led Development of Gene Therapies and Drugs for Alpha-1 Antitrypsin Deficiency
- PMID: 26636478
- PMCID: PMC4692104
- DOI: 10.1089/hum.2015.29012.jmq
Philanthropy and Advocacy-Led Development of Gene Therapies and Drugs for Alpha-1 Antitrypsin Deficiency
Comment on
-
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27. Lancet. 2015. PMID: 26026936 Clinical Trial.
References
-
- de Serres FJ. Worldwide racial and ethnic distribution of α1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122:1818–1829 - PubMed
-
- Chapman KR, Burdon JG, Piitulainen E, et al. ; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360–368 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
